We are excited to share the launch of LIVEDIFF Part 2!

After review and approval by the DSMB, the trial will aim to demonstrate EXL01's safety and efficacy in patients with high-risk of Clostridioides difficile infection (CDI).

CDI remains a major public health concern, with over 120,000 cases and nearly 3,700 deaths annually.

Part 2 of the trial will be randomized, placebo-controlled and double-blind. It will enroll 50 patients across two arms (EXL01 v Placebo).

The trial is supported by the French Ministry of Health and conducted in collaboration with Hospices Civils de Lyon - HCL

‍